Study Condition(s): Nonradiographic Axial Spondyloarthritis
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis (COAST-X)
Study Alias: RHBX
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biologic disease modifying antirheumatic drug (bDMARD) naïve participants with nonradiographic axial spondyloarthritis (nonrad-axSpA).
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Participant must have diagnosis of nonradiographic axial spondyloarthritis (nr-axSpA)
Participant must be able to walk
Participant must have a history of back pain for ≥3 months that started before 45 years of age
Participants must have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDS) for duration of 4 weeks or cannot tolerate NSAIDS.
Participants that are taking NSAIDS must be on a stable dose for at least 2 weeks prior to randomization
Participants must have a history of prior therapy for axSpA for at least 12 weeks prior to screening for the study
Participants must not have radiographic sacroiliitis
Participants must not have received any prior, or are currently receiving treatment with biologics, tumor necrosis factor inhibitors or other immunomodulatory agents
Female participants must not be pregnant or breastfeeding